Satsuma Pharmaceuticals, Inc. announced that Upon completion of the Merger on June 8, 2023, Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company's board of directors, and Ken Takanashi remained a member of the Company's board of directors. Accordingly, each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company's board of directors at the Effective Time. These departures were solely in connection with the Merger and not a result of any disagreement with the Company, its management or its board of directors.

Immediately following the Effective Time, (i) John Kollins ceased serving as President Immediately following the Effective Time, each of the following persons was appointed to the position within the Company opposite their name: (a) Ryoichi Nagata – President, and (b) Shinji Nitanda – Secretary.